Kakkis Emil D's Form 4 filing
Ultragenyx Pharmaceutical Inc. (RARE) · filed Dec 31, 2024
- Accession no.
- 0000950170-24-141485
- Filed
- Dec 31, 2024
- Trade date
- Dec 30, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $495.2K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kakkis Emil DCIK 0001248093 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 30, 2024 | Common Stock | SSaleDisposed | −11,727 | $42.23 | −$495,231.21 | 2,183,985 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.